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Summary
Leishmaniasis provides a biologically relevant model to analyze the heterogeneity of CD4' T
cells and may lead to answering the major question of the mechanism for the preferential induction
of T helper type 1(Thl) and Th2 cells. Using synthetic peptides corresponding to the tandemly
repeating regions of Leishmania proteins, we have identified an epitope that can preferentially
induce the disease-exacerbating Th2 cells in susceptible BALB/c mice. Lymph node cells from
BALB/c mice immunized subcutaneously with the octamer (p183) ofthe repeating 10-mer peptide
EAEEAARLQA proliferated strongly against the peptide as well as the soluble antigen extract
(SolAg) of Leishmania major. The proliferative T cells are CD4+, major histocompatibility
complex class II restricted, and secrete interleukin 4 (IL4) but little or no IL2 and interferon
y when stimulated with the peptide in vitro. T cellsfrom BALB/c mice with progressive disease,
but not from BALB/c mice curedof the infection, recognized this epitope. BALB/c mice injected
subcutaneously withp183 developed significantly exacerbated disease when subsequently challenged
with L. major. Furthermore, subcutaneous injection with p183 prevented the subsequent induction
of resistance against L. major by intravenous immunization with soluble antigen. The T cell
response to p183 is H-2d restricted. Immunization of the genetically resistant B10.D2 mice with
p183 also produced strong T cell responses and exacerbated disease when challenged with L. major.
It is now generally accepted that murine CD4* T cells can
be functionally divided into two subpopulations. Principally,
Thl cells secreting IL2 and IFN-y mediate the classical delayed-
type hypersensitivity, whereas Th2 cells secreting 114 and
IL5 help IgE synthesis (1, 2). In experimental murine leish-
maniasis, a disease caused by the protozoa parasites of Leish-
mania species, it is now clear that Thl cells are host protec-
tive (3, 4), whereas Th2 cells can lead to disease exacerbation
(5, 6), and the outcome of the infection is determined by
the balance of Thl and Th2 cells (7). Thus, 11,4 produced
by Th2 cells can neutralize the macrophage-activating and
leishmanicidal effect of IFN-y produced by Thl cells (8).
From a genomic Leishmania major DNA expression library
Wallis and McMaster (9) selected two clones by using poly-
clonal antibodies raised against L. major membranes. The clones
encoded proteins containing regions oftandemly repeated pep-
tidesof 14 and 10 amino acids, respectively. Regions ofrepeti-
tive peptides are a characteristic of many malaria proteins,
and this feature has been implicated in immune evasion (10).
We therefore decided to investigate the immunogenicity of
the tandemly repeated peptides of leishmanial parasite. Results
reported here demonstrate that the octamer ofthe 10-residue
peptide (EAEEAARLQA) preferentially induces Th2 cells and
promotes disease progression in the genetically highly sus-
ceptible BALB/c mice infected with L. major. This finding
may help todefine the molecular requirement for the preferen-
tial induction of Th2 cells.
Materials and Methods
Mice.
￿
Female BALB/c, CBA, C57BL/10, B10.S mice, 8-12 wk
old, were bred and maintained at the Wellcome Research Labora-
tories, Beckenham, Kent, UK. BALB.b, BALB.k, and B10.D2 mice
of the same age were obtained from Olac Ltd. (Bicester, Oxon).
PeptideSynthesis.
￿
Solid-phase peptide synthesis using established
procedures in "Tea bags" was performed as described by Houghten
(11). Peptides were assembled on Pam-gly resin (Applied Biosystems,
Inc., Foster City, CA) or p-methylbenzyhydrylamine resin, de-
pending on whether free peptides or peptide amides were required.
The octamer configuration was according to Tam (12). Cleavage
of the finished peptides from the resins was achieved with tri-
fluoromethanesulphonic acid (TFA)', as described by Bergof et al.
(13), and the resulting peptides were extracted twice with ether
before lyophilization from solutions in 10% acetic acid. Purity was
'Abbreviations used in this paper . LNC, lymph node cells; SolAg, soluble
antigen extract of promastigotes; TFA, trifluoromethanesulphonic acid.
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218TP54) eluted with a gradient (5-70%) ofacetonitrile in water
containing 0.1% TFA. Peptides were further characterized by amino
acid analysis and by SDS-PAGE, or using a procedure optimized
for low molecular weight proteins (14). Reversed-phase HPLC of
each peptide gave a single peak indicating a homogeneous product.
PAGE confirmed that all peptides migrated at their expected mo-
lecular weight in comparison with standard markers (low molec-
ular weight kit for peptides with molecular weights between 2,510
and 16,950; Sigma Chemical Co., St. Louis, MO). Amino acid anal-
ysis was consistent with the proposed structures(Fig. 1). Although
molar values for p183 were >10% at variance with the expected
value, for glutamic acid/glutamine, sequencing ofpeptide 183 in-
dicated that glu/gln residues did not couple quantitatively, pos-
sibly due to steric hindrance in the octamer structure. This was
seen with more than one batch of p183 and suggests thatthe pep-
tide chains in this octamer contain deletion variants in the glu/gln
residues.
Parasites.
￿
The maintenance, cultivation, and isolation of the
promastigotes stage of the parasite L. major (LV39) havebeen de-
scribed in detail (15). Parasites used for immunization were exposed
to y irradiation (150,000 rad) from a
13'Cs source. After irradia-
tion, the parasites suspension (2 x 10s/ml of PBS) was kept at
4°C and used within 7 d. The parasites thus prepared are non-
replicative and noninfective in vivo and in vitro, and die within
7 d. For animal infection, groups of micewere injected subcutane-
ously (in 0.05 ml PBS) in the left hind footpad with 1-3 x 105
(BALB/c) or 106 (B10M) stationary phase promastigotes. Infec-
tion was also given in the rump with 2 x 10' organisms in 0.1
ml PBS. Some BALB/c mice were irradiated with 550 rad from
a 13'Cs source 4 h before infection in the rump. The lesions that
developed weremeasuredwith a dial calliper. In some experiments,
mice were killed and the footpads removed. The parasite loads in
the footpads were estimated by a method described by Heinzel et
al. (6). Briefly, the footpad tissue was homogenized, and superna-
tants containing the released parasites were serially diluted in
Schneider's medium (Gibco Laboratories, Paisley, UK) containing
30% FCS. Quadruplicate cultures were incubated at 28°C for 3 d
and then pulsed with 1 ACi of [3H]thymidine (Amersham Corp.,
Arlington Heights, IL). Cultures were harvested 18 h later. The
results were expressed as the highest dilution (logio) at which
viable parasites are detectable (2 SD over background cpm of cul-
tures without parasites).
Proliferative T Cell Response.
￿
Draining lymph nodes were re-
moved from mice and made into single cell suspension at 4 x 10,
cells/ml inClicks EHAA medium supplemented with 0.5% fresh
normal mouse serum. The cell suspension (100 /Al) was placed into
microtiter wells (96-well flat-bottomed microtiter plates; Nunc,
Roskilde, Denmark), and antigen (100 Al) was added at the indi-
catedconcentration per well: peptides, 5-0.05 hg; soluble antigen
extract of promastigotes (SolAg) 106-10^ organisms equivalent;
SRBC, 106-10'. [3H]Thymidine incorporation into DNA during
the last 4 h (high specific activity thymidine, 1 pCi/well; Amer-
sham Corp.) of a 4-d culture at 37°C and 5% CO2 was deter-
mined as a measure of proliferation. Cultures were set up in tripli-
cate, and the results are expressed in mean cpm ± 1 SEM. SolAg
was prepared by five cycles of freezing and thawing of 2 x 10s/ml
of stationary phase promastigotes in PBS. The material was then
centrifuged at 8,000g for 10 min at 4°C, and the supernatant was
filtered (0.45-P,m filter; Gelman Scientific, UK) and stored at
-70°C. The protein concentration was 0.76 mg/ml/2 x 10' or-
ganisms, as determined by a BCA assay (Pierce Chemical Co., Rock-
ford, IL), SRBC were kept in Alsever's solution at 4°C, and a sus-
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pension at the required concentration was made freshly after three
washes with PBS.
Lymphokine Assays. Lymph node cells (10'/ml) from im-
munized mice were stimulated for 24-48 h in vitro with 10' or-
ganisms/ml equivalent of SolAg, and the lymphokineactivities in
the cell-free culture supernatants were determined as follows: 11,2
and 11,4 activities were determined using CTL cell line (American
Type Culture Collection, Rockville, MD). mAb anti-11,2 (S4B6,
50 Fag/ml) and anti-114 (11B11, 5,ug/ml) were used to distinguish
the two lymphokines. The CTL cells (10'/50 1A1) were cultured
in 96-well flat-bottomed plates (Nunc) with several dilutions of
the supernatant (100 Wl) and mAb (50 wl) for 36 h at 37°C and
5% COz. The cultures in triplicates were pulsed with 1 PCi/well
high-specific activity [3H]thymidine for the last 4 h before har-
vesting and radioactivity incorporation was counted. The results
are expressed as U/ml by reference to standards of rIIr2 and HIA
(Genzyme, Boston, MA). The IFN-'y activity in the supernatant
was analyzed by a solid-phase immunoradiometric assay using a
laboratoryreference standard ofrecombinant MuIFN-.y derived from
Chinese hamsterovary (CHO) cells calibrated in U/ml as described
previously (16).
Results
Antigenicity ofthe Peptides.
￿
Six peptides corresponding to
the tandemly repeating regions ofproteins encodedby L. major
genes (9) were synthesized: p178, p179, and p180 correspond
to a repetitive peptide of 14 amino acids (Gln Glu Thr Ser
Ala Asn Val Ala Asp Thr Glu Glu Thr Leu), while p181,
p182, and p183 correspond to another repetitive peptide of
10 residues (Glu Ala Glu Glu Ala Ala Arg Leu Gln Ala) .
p178 and p180 are peptide amides, p179 and p182 have an
extra glycine residue on the COOH termini, and p180 and
p183 are of the octamer configuration as detailed in Fig. 1.
Genetically susceptible BALB/c mice developed resistance
to leishmanial infection when they were immunized intrave-
nously or intraperitoneally with lethally irradiated parasites
or soluble parasite antigen. In contrast, they developed ex-
acerbated disease if the immunization was administered sub-
cutaneously (15). This has been attributed to the preferential
induction ofthe protective Th1 cells by the intravenous route
and the activation of the disease-promoting Th2 cells by the
subcutaneous route (7). BALB/c mice were immunized in-
travenously or subcutaneously with the SolAg extract of L.
major promastigotes together with C. parvum, and theirlym-
phoid cells were tested against the peptides for proliferative
response. Mesenteric lymph node cells (LNC) and spleen cells
from mice immunized one to four time intravenously with
SolAg in a range of adjuvants (C. parvum, Al(OH)3, MDP,
saponin, and liposomes) produced little or no response against
any of the peptides tested, but showed significant prolifera-
tion against SolAg (data not shown). In contrast, LNC from
subcutaneously immunized mice developed significant response
to all the six peptides (Fig. 2). The response was antigen specific
as no proliferation was detected against SRBC. The prolifer-
ative response of the LNC against the peptides ranged from
30 to 60% of that stimulated by the SolAg derived from the
whole organism, indicating that the peptides couldbe major
immunogenic components of the SolAg preparation when
presented via the subcutaneous route.Pevddos
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Figure 1.
￿
The amino acid sequence and the theoretical configurations
of the octamer peptides (180 and 183).
LNC were also obtained from BALB/c mice with progres-
sive L. major infection and from BALB/c mice recovered from
the infection as a result of sublethal y irradiationjust before
infection with L. major (17). The former LNC population
is known to contain predominantly Th2 cells secreting IL4
and IL5, whereas the latter are mainly Thl cells producing
IL-2 and IFN-y upon specific antigen stimulation in vitro
(18, 19). When these cells were cultured with the peptides
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Figure 2.
￿
Proliferative response of LNC from mice immunized with
soluble L. majorantigens. BALB/c mice were immunized subcutaneously
in the funk with four weekly doses of SolAg (2 x 107 organisms equiva-
lent) mixed with 100,ug of C. parvum or C. parvum alone. The draining
LN were removed 7 d after the last injection, and LNC were tested in
vitro against graded doses of the peptides, SolAg, or SRBC. The data
shown here are the optimal proliferative responses.
in vitro, only p183 elicited a positive response, which was
only found with the LNC from mice with progressive dis-
ease (Table 1). None of the peptide was recognized by the
LNC from mice recovered from the infection.
Immunogenicity of the Peptides.
￿
BALB/c mice were then
injected subcutaneously with 100 lAg ofthe peptides in CFA.
LNC were tested 7 or 14 d later for proliferative response
in vitro against the peptide as well as SolAg. Only p183 showed
a strong response against itself and a significant proliferation
against the SolAg (Fig. 3, a and b). LNC from p183-primed
mice also responded to p181 and p182 to a degree similar as
that ofSolAg (data not shown). The response is antigen specific
in that the LNC did not recognize SRBC or p180, the oc-
tamer configuration of the 14 residue repeat.
3
SolAg = 106 organism equivalent/well. Peptides = 5 tsl/well. Figures = mean t 1 SEM of triplicate cultures, after subtracting background
cpm in cultures without antigen (2.5 f 0.1).
t BALB/c mice infected in the shaved rump with 2 x 107 L. major promastigotes 90 d previously, with mean lesion size of 7.5 ± 1.0 mm and
progressing.
S BALB/c mice were irradiated with 550 rad and infected in the rump 4 h later with 2 x 107 promastigotes. LNC were obtained 125 d later when
lesions had completely healed.
Table 1. The Proliferative Response of LNC from Infected and Cured BALB/c Mice against Peptides
Antigen in vitro
and SolAg
LNC from BALB/c Mice SolAg p178 p179 p180 p181 p182 p183
cpm x 10"
With progressive diseaset 52 ± 2 <1 .0 <1.0 <1 .0 2.1 ± 0.1 3.1 ± 0.2 21.2 ±
Recovered from infections 83 ± 5 <1 .0 <1 .0 <1 .0 <1 .0 <1 .0 <1.01362
Characterization ofT CellsInduced byp183.
￿
The prolifera-
tive response ofLNC from mice immunized subcutaneously
withp183 and CFA was inhibited by anti-CD4 antibody (YTS
191) and anti-I-Ad antibody (MKD.6), but not by anti-CD8
antibody (YTS 169) or anti-I-A' antibody (Y3P) (Fig. 4).
The response induced by p183 is therefore due to class II-re-
stricted CD4+ cells. No cytotoxic T cell activity was de-
tected when spleen or LN cells from peptide- or L. major-im-
munized mice were tested against a tumour (P815) cell line
coated with various concentrations of the peptides in a stan-
dard cytotoxic T cell assay (5 d in vitro stimulation followed
by a 5-18-h assay, data not shown). The LNC from BALB/c
mice immunized 7 d previously with p183 or p180 in CFA
were cultured for 24-48 h with 0.5 kg/ml ofp183 in vitro.
The culture supernatants ofcellsfrom mice immunized with
p183 and CFA were found to contain high levels of IIJ4 but
little or no IL-2 or IFN-y (Table 2). IL2, IIT4, or IFN-y
were not detectable in any of the nonproliferating cultures.
These results therefore indicate that p183 induces predomi-
nantly Th2 cells when administered via the percutaneous route.
The Effect ofp183on Disease Progression.
￿
Since among the
six peptides tested, only p183 can induce significant immuno-
logical responses in vivo, experiments were therefore carried
out to test its ability to influence the course of infection in
BALB/c mice. When BALB/c mice were injected four times
intravenously with SolAg, they developed substantial resis-
tance to a challenge infection (Fig. 5). However, no significant
protection was induced by similar intravenous immunization
with p183 with or without C. pamum. In contrast, mice in-
jected subcutaneously with p183 with or without C. parvum
consistently developed significantly exacerbated lesions after
challenge infection compared with unimmunized controls (Fig.
5). These results suggest that p183 may be a disease-
exacerbating epitope when administered via the percutaneous
route. This is confirmed by the result of the following ex-
periment. BALB/c mice were given four weekly subcutaneous
injections of p183 with C. parvum or C. parvum alone, and
then were immunized four times intravenously with a 2 x
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Figure 3. Induction of specific
proliferative T cell response in BALB/c
mice by peptide 183. BALB/cmice were
immunized subcutaneously in the flanks
with: (a) 100 F+g of p183 emulsified in
CFA; or (b) CFAalone. Draining lymph
node cells were harvested 7 d later and
stimulated in vitro against graded doses
of p183, p180, SolAg, or SRBC. The
results are expressed as [3H]thymidine
incorporation in cpm, after subtracting
background response in the absence of
antigen (1,900 cpm). p180 is included
here to show that the response is not
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107 organism equivalent of SolAg. The resistance developed
in the intravenously immunized mice was not affected byprior
C. pavum injection alone, but was completely abrogated by
the prior subcutaneous injection of p183 + C. parvum (Fig.
6). Disease exacerbation by subcutaneous immunization is
leishmanial specific, as reported previously (15). p183 induced
little or no delayed-type hypersensitivity to itselfor toSolAg
(data not shown).
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Figure 4.
￿
BALB/c mice were immunized subcutaneously in the flanks
with 100 jig p183 in CFA. Draining LNC were harvested 7 d later and
stimulated in vitro with graded doses ofp183 in the presence of various
antibodies as indicated. Antibody (10 Wg/well) was added at the start of
the culture. All antibodies were ammonium sulphate precipitated ascitic
fluids: anti-CD4 (YTS 191) and anti-CD8 (YTS 169) were from Dr. H.
Waldmann, Cambridge University; anti-I-Ad (MKD6) and anti-I-As
(Y3P) were from Dr.J. Tite, Wellcome Biotech. The results were expressed
as in Fig. 2.Table 2 .
￿
Lymphokine Production by LNC from BALB/c Mice
Immunized with Peptides
BALB/c mice were injected subcutaneously with 100 lAg of peptide in
CFA, and the draining LNC were cultured with Fcg/ml of p183 . The
supernatants were harvested 24 h later and assayed for lymphokine ac-
tivities as described in Materials and Methods .
Genetic Restriction ofp183.
￿
Several strains of inbred mice
(BALB/c, BALB.b, BALB.k, B10.D2, CBA, B10, and B10.S)
were tested for their ability to respond to the six peptides.
The mice were immunized with the peptides in CFA, and
theLNC was stimulated by graded concentrations of the pep-
tides in vitro . The results in Table 3 clearly demonstrate that
the response to p183 is H-2d restricted . The other five pep-
tides were not able to induce a detectable response in all the
strains of mice tested (data not shown) .
Effects ofp183 in the Genetically ResistantB10M Mice
￿
Since
B10.D2 (H-2d) is genetically resistant to L . major infection
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Figure 5.
￿
The effect of immunization with p183 on the disease devel-
opment in BALB/c mice. Groups of mice were injected subcutaneously
in the flanks with 100 ug of p183, or intravenously in the tail veins with
100 ug of p183, or intravenously with a 2 x 107 equivalent of SolAg.
Each mouse received four weekly doses of the antigen as indicated . The
animals were challenged in the footpad with 3 x 105 L. major pro-
mastigotes 7 d after the last injection, and the lesions that developed sub-
sequently in the footpad were measured weekly . Lesion size is expressed
as increase in footpad thickness in 10- 1 mm, being the difference between
the infectedand uninfected footpad. Vertical bars = 1SEM, n = 5 . Similar
results were obtained whether the peptide was injected with or without
C parvum.
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Figure 6.
￿
Groups of micewere injected fourtimes subcutaneouslywith
100,ug of p183 + 100 Ag ofC parvum, 100 Ag of C . parvum alone, or
were uninjected . All mice except controls were then injected four times
intravenously with a 2 x 107 equivalent of SolAg. All injections were
given weekly. They were challenged in the footpads with 105 L . major
promastigotes 7 d after the last intravenous immunization . The lesions
that developed were measured as in Fig. 5, and the lesion sizes at day 54
post-infection were shown . Vertical bars = 1 SEM, n = 8-10. The mice
were killed and the footpads removed . The parasite load in the footpads
were estimated as described in Materialsand Methods . Figures in paren-
theses represent the logio dilutions of culture at which viable parasites
were detectable .
and is responsive to p183, it is of interest to test whether
p183 can also influence the disease progression in this strain
of mice . Groups of B10.D2 mice were given four weekly sub-
cutaneous or intravenous injections of p180 and C. parvum
and then challenged in the footpads with L. major . Table 4
shows that the mice injected subcutaneously with p183 and
C. parvum developed significantly exacerbated disease com-
pared with control mice immunized with C. parvum alone-
p183 administered intravenously had little or no effect. It
Table 3.
￿
Genetic Restriction of T Cell Response to p183
Antigen in vitro
Strain H-2 p183 p182 p180 SolAg
cpm x 10,
BALB/c
￿
d
￿
54 .8 ± 5.2 7.7 ± 0.8 <1 .0
BALB.b b <1 .0 <1 .0 <1.0
BALBA k 1.0 <1 .0 <1.0
CBA k <1.0 <1 .0 <1.0
B10 b <1 .0 <1 .0 <1.0
B10.S s <1 .0 <1.0 <1.0
B10.D2
￿
d
￿
40.3 ± 3.2 3.7 ± 1.5 <1 .0
5.2 ± 0.5
<1 .0
<1 .0
<1 .0
<1 .0
<1.0
3.5 ± 0.8
Mice were injected subcutaneously with 100 Ag of p183 in CFA and
LNC were harvested 7 d later and stimulated in vitro with 5 ag/well
of peptide or 106 organisms/well of SolAg.
" Figures are the mean of triplicate cultures ± 1 SEM, after subtracting
background cpm in cultures without antigen (3.1 t 0.2).
Immunization IL-2 IFN-y
,U/ml
IL-4
C .P.
L.m .
L.m .
p183 + CFA 12 3 240 183+
CFA 10 2 <1.0 C .P . L.m .
p180 + CFA 5 2 <1.0Table 4.
￿
Effect of p183 Immunization on Disease Development
in B10.D2 Mice
Immunization
p183 + C. parvum (s .c.)
p183 + C. parvum (i.v.)
C. parvum alone (s.c.)
C. parvum alone (i.v.)
Control
Discussion
Lesion size
Mice wereimmunized weekly with 100 t~g p183 + 100 kg C. parvum
or C. pamum alone and challenged in the footpad with 106 promastigotes
7 d after the last immunization.
Lesions were measured at various timespost-infection. Figures are mean
± 1 SEM, n = 5; those underlined are significantly different (p < 0.05)
from controls.
should be noted that LNC from the resistant B10.D2 mice
obtained at various stages of the infection did not produce
a significant proliferative response to p183 in vitro (data not
shown), although they responded vigorously to SolAg.
Data presented in this report suggest that the octamer of
a tandemly repeating peptide from L. major could induce ex-
acerbated disease when administered subcutaneously to ge-
netically susceptible or resistant strains of mice in the mu-
rine cutaneous leishmaniasis model. Furthermore, evidence
was also presented that the peptide did so by preferentially
inducing Th2 cells, which secrete IL-4 but little or no IL-2
and IFN-y (1) . This finding extends the earlier observation
that in the cutaneous leishmanial system, Th2 cells are dis-
ease promoting (6, 7, 20); it may also provide a molecular
model for the selective induction of these cells.
Scott et al. (20) reported that Thl and Th2 cells were
separately induced by two noncrossreacting fractions of L.
major antigen extract. Jardim et al. (21) showed that a syn-
thetic peptide (PT3), corresponding to a conserved region
of the major surface glycoprotein (gp63) ofLeishmania, could
activate Thl type cells and induce a host-protective response
in BALB/c mice. We also found that synthetic peptides
covering a similar region of the gp63 molecule couldprefer-
entially stimulate Thl cells in vivo and protect CBA mice
against L. major infection (22). This implies that Thl and
Th2 cells may have different antigen-recognition repertoires.
Others have argued that Thl and Th2 cells are derived from
a common precursor cell and the eventualdifferentiation into
these two subsets is influenced by accessory signals such as
local cytokines (23-25). There is now evidence that synthetic
peptides representing single Th epitopes can induce both Thl
and Th2 clones (Gao, X .-M., F. Y Liew, K. Bottomly, A.
Meager, and J. P. Tite, manuscript submitted for publica-
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tion). Data reported in the present study show that certain
epitopes (e.g., p183) can nevertheless preferentially induce a
subset of Th cells. However, such a bias is likely to be due
to the mode of antigen presentation rather than repertoire
selection,because p183 can only induce Th2 cells via the sub-
cutaneous route. Immunization with p183 by the intravenous
route provoked little or no host response. Other factors, such
as the MHC gene products, may also influence the induction
of CD4+ T cell subsets. 1-A' mice were found to selectively
activate Thl cells, whereas 1-Ab mice exhibited selective ac-
tivation of Th2 cells in response to collagen IV (26).
The crucial role of APC is also underlinedby the fact that
only the octamer configuration of the peptide can induce a
significant immune response. The monomers (p181, p182),
although recognizable by T cellsfrom mice immunized with
SolAg in vitro (Fig. 2), were not able to induce a T cell re-
sponse. The mechanism by which the octamer p183 is
processed and presented to T cells leading to the preferential
activation of Th2 cells is unknown. During infection,T cells
from the susceptible mice only were activated, demonstrating
the complexity of this process. Normally, susceptible BALE/c
mice and DBA/2 mice (unpublished results) contain Th2 cells
recognizing p183 during the course ofinfection. In contrast,
T cells from BALB/c mice that had been rendered resistant
to L. major infection by prior sublethal irradiation did not
respond to p183 or its monomeric forms (Table 1). Similarly,
the highly resistant B10.D2 mice also did not produce a de-
tectable T cell response to p183 during L. major infection,
although they responded vigorously to p183 when immunized
subcutaneously with p183 plus CFA (Table 3). Thus, during
natural infection, the genetically controlled innate resistance
or susceptibility to the parasite profoundly influences the
presentation of the tandemly repeating 10-mer epitope
(EAEEAARLQA) to the Th cell. Whether such preferential
activation of Th2 cells is controlled by accessory signals such
as cytokines is currently being investigated.
The T cell response to p183 is H-2d restricted. However,
mice of other H-2 haplotypes with the BALB/c background
are also susceptible to L. major infection. BALRb and BALB.k
mice, although less vulnerable to L. major infection compared
with BALB/c mice, nevertheless develop disseminated dis-
ease with fatal outcome (27). Thus, the induction of Th2
cells by p183 epitope is but one of several mechanisms capable
of influencing the outcome of leishmanial infection.
In malaria, it has been proposed that regions of repetitive
peptides may play a role in immune evasion and thus con-
tribute to chronic infection (28, 29) by over stimulating B
cells with otherwise too low an affinity for the antigen to
be activated. This may result in the failure of the host to se-
lect B cell clones capable of synthesizing higher affinity anti-
body. The demonstration here that a tandemly repeating. pep-
tide ofLeishmania, a distinct protozoa that also causes chronic
infection, induces disease exacerbation suggests that some of
these molecules may serve a general function by conferring
a selective advantage to protozoa parasites. The finding here
also suggests that they do so by preferentially inducing Th2
cells, which secrete IL-4 neutralizing the macrophage-activating
function of IFN--y produced by Thl cells (8).
Can Activate T Helper Type 2 Cells
Week 2
x
Week
10- i
5
mm'
Week 10
1 .5 ± 0.2 5.8 ± 0.7 3.2 ± 0.6
1.1 ± 0.1 2.5 ± 0.2 1.0 ± 0.1
1 .3 ± 0.1 2.0 ± 0.1 1.3 ± 0.1
1.0 ± 0.1 1.9 ± 0.2 1.0 ± 0.1
0.5 ± 0.1 2.8 ± 0.2 1 .2 ± 0.1References
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